PerkinElmer has accomplished its acquisition of Oxford Immunotec after beforehand asserting its intention in January this yr.
Prahlad Singh, President and CEO of PerkinElmer, mentioned: “Oxford Immunotec’s international position within the battle towards tuberculosis, notably its proprietary product, the T-SPOT.TB take a look at, and the operations it has constructed are exceptional. We acknowledge the distinct scientific and logistical advantages of testing and see an ideal alternative to leverage our automation capabilities and entry to enterprise channels to carry TB testing to extra clients all over the world. “
Oxford Immunotec, based mostly in Abingdon, UK, is acknowledged as a world chief in proprietary take a look at kits for latent tuberculosis. Its interferon gamma launch assay (IGRA) identifies individuals contaminated with tuberculosis.